Ads attract fewer warning letters

Share this article:
Warning and untitled letters on broadcast and print DTC ads have plummeted since PhRMA's adoption of its Guiding Principles on DTC in August 2005.

In 2004, the FDA's Division of Drug Marketing, Advertising and Communications issued 13 warning and untitled letters on DTC ads. From January to August of 2005, the agency issued 17 warning and untitled letters on DTC ads. Since then, it has issued two—neither of which concerns broadcast or print, the media covered by PhRMA's voluntary code. “It reflects a significant change in attitude at DDMAC,” said John Kamp, executive director of the Coalition for Healthcare Communications.  

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...